Recombinant Human Interferon-beta1b

Accession P01574

GeneID 3456

Source Escherichia coli.

Molecular Weight Approximately 20.0 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.

Quantity 2µg/10µg/1mg

AA Sequence MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN

Purity > 97 % by SDS-PAGE and HPLC analyses.

Biological Activity Fully biologically active when compared to standard. The specific activity determined by an anti-viral assay is no less than 3.0 × 107 IU/mg.

Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4, containing 2 % HSA and 3 % mannitol.

Endotoxin Less than 1 EU/µg of rHuIFN-β1b as determined by LAL method.

Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.

- 1 month, 2 to 8 °C under sterile conditions after reconstitution.

- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Usage This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

Reference 1. Yoshino A, Tashiro S, Ogino A, et al. 2011. Int J Oncol, 39: 529-42.

2. Farrell RA, Marta M, Gaeguta AJ, et al. 2012. Rheumatology (Oxford), 51: 590-9.

3. Breckpot K, Corthals J, Bonehill A, et al. 2005. J Leukoc Biol, 78: 898-908.

4. Oger J, Francis G, Chang P. 2005. J Neurol Sci, 237: 45-52.

5. Giorelli M, Livrea P, Trojano M. 2005. J Interferon Cytokine Res, 25: 395-406.

Background IFN-βs are proteins produced by many cell types including lymphocytes (NK cells, B-cells and T-cells), macrophages, fibroblasts, endothelial cells, osteoblasts and others. They have antiviral activity that it is mainly involved in innate immune response. The IFN-β family has 2 subtypes，which are IFN-β1 (IFNB1) and IFN-β3 (IFNB3) (a gene designated IFN-β2 is actually IL-6). IFN-β1 is used as a treatment for multiple sclerosis as it reduces the relapse rate.